THACI, D.; PAPP, K.; GORDON, K.; MORITA, A.; GOODERHAM, M.; FOLEY, P.; ALEMANO, E.; KISA, R.; ELBEZ, Y.; REN, H.; BANERJEE, S. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S12, 2019. DOI: 10.25251/skin.3.supp.12. Disponível em: https://jofskin.org/index.php/skin/article/view/739. Acesso em: 19 apr. 2024.